Hypoxia Promotes Syndecan-3 Expression in the Tumor Microenvironment.

cancer immunotherapy hypoxia solid tumors syndecan-3 tumor microenvironment (TME)

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2020
Historique:
received: 27 07 2020
accepted: 10 09 2020
entrez: 29 10 2020
pubmed: 30 10 2020
medline: 16 6 2021
Statut: epublish

Résumé

The syndecan (Sdc) family is comprised of four members of cell surface molecules (Sdc-1 to 4) with different biological functions. Syndecan-3 (Sdc-3) is known to be mainly expressed in the brain and nervous tissue and plays a key role in development, cell adhesion, and migration. Recent studies point to important roles for Sdc-3 in inflammatory disease, but the patterns of expression and significance of Sdc-3 in cancer remains unexplored. Here we show that Sdc-3 expression is upregulated on several cancer types, especially in solid tumors that are known to be hypoxic. The Cancer Genome Atlas program (TCGA) data demonstrated that Sdc-3 expression in the tumor microenvironment positively correlates with a hypoxia gene signature. To confirm a potential cause-effect, we performed experiments with tumor cell lines showing increased expression upon

Identifiants

pubmed: 33117401
doi: 10.3389/fimmu.2020.586977
pmc: PMC7561406
doi:

Substances chimiques

SDC3 protein, human 0
Syndecan-3 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

586977

Informations de copyright

Copyright © 2020 Prieto-Fernández, Egia-Mendikute, Bosch, García del Río, Jimenez-Lasheras, Antoñana-Vildosola, Lee and Palazon.

Références

Immunity. 2014 Oct 16;41(4):518-28
pubmed: 25367569
J Clin Invest. 2004 Nov;114(9):1354-60
pubmed: 15520868
Arthritis Res Ther. 2019 Jul 12;21(1):172
pubmed: 31300004
J Histochem Cytochem. 2015 Apr;63(4):280-92
pubmed: 25575567
FEBS J. 2010 Oct;277(19):3863
pubmed: 20812984
Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6062-7
pubmed: 15075390
Front Immunol. 2020 Jan 09;10:3031
pubmed: 31998313
J Biol Chem. 2012 Nov 23;287(48):40339-49
pubmed: 23060448
J Cell Mol Med. 2011 May;15(5):1013-31
pubmed: 21155971
Cold Spring Harb Perspect Biol. 2011 Jul 01;3(7):
pubmed: 21690215
BMC Cancer. 2013 Jan 26;13:34
pubmed: 23351331
Front Endocrinol (Lausanne). 2018 Mar 06;9:69
pubmed: 29559954
J Clin Invest. 2016 Oct 3;126(10):3672-3679
pubmed: 27482883
FEBS J. 2010 Oct;277(19):3904-23
pubmed: 20840587
Nat Rev Cancer. 2015 Aug;15(8):457-72
pubmed: 26205340
Curr Cancer Drug Targets. 2020;20(6):461-470
pubmed: 32271695
BMC Genomics. 2013 Sep 20;14:632
pubmed: 24053356
Cells. 2019 Sep 14;8(9):
pubmed: 31540045
Nat Biotechnol. 2020 Jun;38(6):675-678
pubmed: 32444850
J Neurooncol. 2006 Mar;77(1):25-32
pubmed: 16132527
Am J Pathol. 2005 Sep;167(3):627-35
pubmed: 16127144
Cancer Res. 2018 Oct 1;78(19):5492-5503
pubmed: 30206177
J Cell Mol Med. 2017 Nov;21(11):3023-3043
pubmed: 28557334
Cancer Sci. 2018 Sep;109(9):2919-2936
pubmed: 29968393
FEBS J. 2017 Jan;284(1):27-41
pubmed: 27790852
Semin Oncol. 2015 Jun;42(3):378-86
pubmed: 25965356
Genes Dev. 2010 Mar 1;24(5):491-501
pubmed: 20194441
Genes Dev. 2004 Sep 15;18(18):2231-6
pubmed: 15371336
Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19464-9
pubmed: 18040049
Nat Rev Drug Discov. 2019 Mar;18(3):197-218
pubmed: 30610226
Nat Metab. 2019 Apr;1(4):431-444
pubmed: 31984309
F1000Res. 2013 Dec 09;2:270
pubmed: 24555114
J Cell Sci. 2007 Jun 1;120(Pt 11):1829-32
pubmed: 17515480
Br J Pharmacol. 2019 Jan;176(1):67-81
pubmed: 29931674
Clin Cancer Res. 2004 Aug 1;10(15):5178-86
pubmed: 15297422
Annu Rev Cell Dev Biol. 2010;26:89-114
pubmed: 20565253
Oncogenesis. 2018 Jan 24;7(1):10
pubmed: 29362402
Dev Cell. 2017 Oct 9;43(1):24-34.e5
pubmed: 28943240
Clin Cancer Res. 2005 Jun 15;11(12):4282-8
pubmed: 15958608
PLoS One. 2015 Jan 24;10(1):e0117404
pubmed: 25617766
FASEB J. 2014 Jun;28(6):2455-65
pubmed: 24558194
Nat Cell Biol. 2016 Apr;18(4):356-65
pubmed: 27027486
Science. 2016 Apr 8;352(6282):189-96
pubmed: 27124452
Cell Tissue Res. 2010 Jan;339(1):31-46
pubmed: 19597846
World J Gastroenterol. 2017 Jun 7;23(21):3907-3914
pubmed: 28638231
Nat Rev Cancer. 2014 Jun;14(6):430-9
pubmed: 24827502
Cell. 2016 Jul 28;166(3):740-754
pubmed: 27397505
Int J Immunopathol Pharmacol. 2009 Jul-Sep;22(3):627-38
pubmed: 19822079
J Pathol. 1998 Jul;185(3):290-7
pubmed: 9771483

Auteurs

Endika Prieto-Fernández (E)

Cancer Immunology and Immunotherapy Lab, Centre for Cooperative Research in Biosciences CIC bioGUNE, Basque Research and Technology Alliance, Derio, Spain.

Leire Egia-Mendikute (L)

Cancer Immunology and Immunotherapy Lab, Centre for Cooperative Research in Biosciences CIC bioGUNE, Basque Research and Technology Alliance, Derio, Spain.

Alexandre Bosch (A)

Cancer Immunology and Immunotherapy Lab, Centre for Cooperative Research in Biosciences CIC bioGUNE, Basque Research and Technology Alliance, Derio, Spain.

Ana García Del Río (A)

Cancer Immunology and Immunotherapy Lab, Centre for Cooperative Research in Biosciences CIC bioGUNE, Basque Research and Technology Alliance, Derio, Spain.

Borja Jimenez-Lasheras (B)

Cancer Immunology and Immunotherapy Lab, Centre for Cooperative Research in Biosciences CIC bioGUNE, Basque Research and Technology Alliance, Derio, Spain.

Asier Antoñana-Vildosola (A)

Cancer Immunology and Immunotherapy Lab, Centre for Cooperative Research in Biosciences CIC bioGUNE, Basque Research and Technology Alliance, Derio, Spain.

So Young Lee (SY)

Cancer Immunology and Immunotherapy Lab, Centre for Cooperative Research in Biosciences CIC bioGUNE, Basque Research and Technology Alliance, Derio, Spain.

Asis Palazon (A)

Cancer Immunology and Immunotherapy Lab, Centre for Cooperative Research in Biosciences CIC bioGUNE, Basque Research and Technology Alliance, Derio, Spain.
Ikerbasque, Basque Foundation for Science, Bilbao, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH